Abstract:The injury-triggered reocclusion (restenosis) of arteries treated with angioplasty to relieve atherosclerotic obstruction remains a challenge due to limitations of existing therapies. A combination of magnetic guidance and affinity-mediated arterial binding can pave the way to a new approach for treating restenosis by enabling efficient site-specific localization of therapeutic agents formulated in magnetizable nanoparticles (MNPs) and by maintaining their presence at the site of arterial injury throughout the vulnerability period of the disease. In these studies, we investigated a dual-targeted antirestenotic strategy using drug-loaded biodegradable MNPs, surface-modified with a fibrin-avid peptide to provide affinity for the injured arterial wall. The MNPs were characterized with regard to their magnetic properties, efficiency of surface functionalization, disassembly kinetics, and interaction with fibrin-coated substrates. The antiproliferative effects of MNPs formulated with paclitaxel were studied in vitro using a fetal cell line (A10) exhibiting the defining characteristics of neointimal smooth muscle cells. Animal studies examined the efficiency of combined (physical/affinity) MNP targeting to stented arteries in Sprague Dawley rats using fluorimetric analysis and fluorescent in vivo imaging. The antirestenotic effect of the dual-targeted therapy was determined in a rat model of in-stent restenosis 28 days post-treatment. The results showed that MNPs can be efficiently functionalized to exhibit a strong binding affinity using a simple two-step chemical process, without adversely affecting their size distribution, magnetic properties, or antiproliferative potency. Dual-targeted delivery strongly enhanced the localization and retention of MNPs in stented carotid arteries up to 7 days post-treatment, while minimizing redistribution of the carrier particles to peripheral tissues. Of the two targeting elements, the effect of magnetic guidance was shown to dominate arterial localization (p = 0.004 vs. 0.084 for magnetic targeting and peptide modification, respectively), consistent with the magnetically driven MNP accumulation step defining the extent of the ultimate affinity-mediated arterial binding and subsequent retention of the carrier particles. The enhanced arterial uptake and sustained presence of paclitaxel-loaded MNPs at the site of stent deployment were associated with a strong inhibition of restenosis in the rat carotid stenting model, with both the neointima-to-media ratio (N/M) and % stenosis markedly reduced in the dual-targeted treatment group (1.62 ± 0.2 and 21 ± 3 vs. 2.17 ± 0.40 and 29 ± 6 in the control animals; p < 0.05). We conclude that the dual-targeted delivery of antirestenotic agents formulated in fibrin-avid MNPs can provide a new platform for the safe and effective treatment of in-stent restenosis.

Dual Targeting of Therapeutics to Endothelial Cells: Collaborative Enhancement of Delivery and Effect.

Vascular Immunotargeting to Endothelial Determinant ICAM-1 Enables Optimal Partnering of Recombinant Scfv-Thrombomodulin Fusion with Endogenous Cofactor

The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention.

A two-pronged approach to regulate the behaviors of ECs and SMCs by the dual targeting-nanoparticles

Targeted Delivery of Therapeutics to Endothelium

Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy

Enhanced Endothelial Cell Delivery for Repairing Injured Endothelium via Pretargeting Approach and Bioorthogonal Chemistry

Dual-targeting Fucoidan-Based Microvesicle for Arterial Thrombolysis and Re-Occlusion Inhibition

Targeted Delivery of a Combination Therapy Consisting of Combretastatin A4 and Low-Dose Doxorubicin Against Tumor Neovasculature.

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine

Endothelial Targeting of a Recombinant Construct Fusing a PECAM-1 Single-Chain Variable Antibody Fragment (scfv) with Prourokinase Facilitates Prophylactic Thrombolysis in the Pulmonary Vasculature

BRAIDing receptors for cell-specific targeting

Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy

Synergistically Enhanced Tumor Uptake via Dual-Targeting of CD105 and EGFR Using a "Click" Heterodimer

Advanced Drug Delivery Systems That Target the Vascular Endothelium.

Directing Cell Delivery to Murine Atherosclerotic Aortic Lesions via Targeting Inflamed Circulatory Interface using Nanocarriers

Nanocarrier Design for Dual-Targeted Therapy of In-Stent Restenosis

Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display

Abstract 139: Precision Nanomedicine Targeting Novel Endothelial Mechano-sensing Mechanisms To Treat Vascular Diseases

Endothelial Cell Membrane-Based Biosurface for Targeted Delivery to Acute Injury: Analysis of Leukocyte-Mediated Nanoparticle Transportation

Flow Shear Stress Differentially Regulates Endothelial Uptake of Nanocarriers Targeted to Distinct Epitopes of PECAM-1.